NASDAQ:SKYE Skye Bioscience (SKYE) Stock Price, News & Analysis $0.86 +0.02 (+2.15%) As of 10:27 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Skye Bioscience Stock (NASDAQ:SKYE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Skye Bioscience alerts:Sign Up Key Stats Today's Range$0.84▼$0.8850-Day Range$0.69▼$2.2352-Week Range$0.50▼$12.72Volume37,290 shsAverage Volume65,049 shsMarket Capitalization$3.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Skye Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the endocannabinoid system, a network involved in metabolism, inflammation and immune regulation. The company is based in San Diego, California, and develops drug candidates for conditions in which endocannabinoid signaling may contribute to disease. Skye’s lead program is nimacimab, an investigational monoclonal antibody designed to inhibit the cannabinoid 1 (CB1) receptor outside the central nervous system. The company is studying nimacimab for metabolic and inflammatory diseases, including obesity and metabolic dysfunction-associated steatohepatitis (MASH). Its approach is intended to address the potential therapeutic benefits of CB1 modulation while limiting central nervous system effects associated with earlier CB1-targeting medicines. The company has also investigated ophthalmic applications of endocannabinoid-system modulation, including SBI-100 Ophthalmic Emulsion for eye diseases such as glaucoma. Skye’s research and clinical development activities are conducted through collaborations with investigators, clinical research organizations and other industry partners as its programs advance through clinical testing.AI Generated. May Contain Errors. Read More Skye Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks32nd Percentile Overall ScoreSKYE MarketRank™: 1.62281278779 of 5 starsSkye Bioscience scored higher than 32% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingSkye Bioscience has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Amount of Analyst CoverageSkye Bioscience has only been the subject of 1 research reports in the past 90 days.Read more about Skye Bioscience's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Skye Bioscience are expected to grow in the coming year, from ($5.04) to ($4.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Skye Bioscience is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Skye Bioscience is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSkye Bioscience has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.11% of the float of Skye Bioscience has been sold short.Short Interest Ratio / Days to CoverSkye Bioscience has a short interest ratio ("days to cover") of 6.28.Change versus previous monthShort interest in Skye Bioscience has recently decreased by 7.84%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSkye Bioscience does not currently pay a dividend.Dividend GrowthSkye Bioscience does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.60 News SentimentSkye Bioscience has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Skye Bioscience this week, compared to 5 articles on an average week.Search Interest1 people have searched for SKYE on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Skye Bioscience to their MarketBeat watchlist in the last 30 days. Company Ownership1.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Skye Bioscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $889,198.00 in company stock.Percentage Held by Insiders6.20% of the stock of Skye Bioscience is held by insiders.Percentage Held by Institutions21.09% of the stock of Skye Bioscience is held by institutions.Read more about Skye Bioscience's insider trading history. Receive SKYE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Skye Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SKYE Stock News HeadlinesSkye Bioscience (NASDAQ:SKYE) Stock Price Down 4.8% - Here's WhyNovember 7, 2026 | americanbankingnews.comSkye Bioscience consensus price target decreased by 75% to $16.32November 2, 2026 | msn.comSocial Security’s trust fund runs short in 2032. Guess who controls Congress.Social Security's retirement trust fund is projected to run dry in late 2032, per the 2026 Trustees Report. After that, only about 78% of scheduled benefits can be paid unless Congress acts. Higher taxes, smaller checks or more borrowing are all on the table. The morning after Democrats took Congress, gold jumped almost 3% and silver jumped 4%. If you count on Social Security for any part of your retirement, a backup plan matters before 2032.November 11 at 1:00 AM | Priority Gold (Ad)Il direttore di Skye Bioscience Andrew Schwab vende azioni per $239.555September 25, 2026 | it.investing.comSkye Bioscience average analyst price target raised 10.29% to $61.20September 15, 2026 | msn.comSkye Bioscience (SKYE) shares rise 6% after hours: Here's what's driving the moveAugust 26, 2026 | msn.comSkye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks TranscriptAugust 14, 2026 | seekingalpha.comSkye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in FinancingsAugust 14, 2026 | globenewswire.comSee More Headlines SKYE Stock Analysis - Frequently Asked Questions How have SKYE shares performed this year? Skye Bioscience's stock was trading at $5.9976 on January 1st, 2026. Since then, SKYE stock has decreased by 86.0% and is now trading at $0.8390. How were Skye Bioscience's earnings last quarter? Skye Bioscience, Inc. (NASDAQ:SKYE) released its quarterly earnings results on Friday, August, 14th. The company reported ($0.27) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.02. When did Skye Bioscience's stock split? Skye Bioscience shares reverse split on Monday, August 24th 2026.A 1-8 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, August 23rd 2026. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did Skye Bioscience IPO? Skye Bioscience (SKYE) raised $100,000 in an initial public offering (IPO) on Thursday, April 11th 2024. The company issued 2,000,000 shares at a price of $0.05 per share. How do I buy shares of Skye Bioscience? Shares of SKYE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Skye Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Skye Bioscience investors own include Emerald Health Therapeutics (EMHTF), NVIDIA (NVDA), Tesla (TSLA), Ford Motor (F), Canopy Growth (CGC), Editas Medicine (EDIT) and Intel (INTC). Company Calendar Last Earnings8/14/2026Today11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 SKYE's financial health is in the Red zone, according to TradeSmith. SKYE has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SKYE Previous SymbolOTCMKTS:EMBI CIK1516551 Webskyebioscience.com Phone858-410-0266FaxN/AEmployees12Year Founded2012Profitability EPS (Trailing Twelve Months)($10.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$55.92 million Net MarginsN/A Pretax MarginN/A Return on Equity-329.08% Return on Assets-201.79% Debt Debt-to-Equity RatioN/A Current Ratio0.95 Quick Ratio0.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.00 per share Price / Book0.17Miscellaneous Outstanding Shares4,428,000Free Float4,153,000Market Cap$3.79 million OptionableOptionable Beta3.13 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:SKYE) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored55+? Elon’s Gift…James Altucher points to Elon Musk's latest FCC filing as a potential turning point for retirees relying on So...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
